TrialScientific reports2021

Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.

Nicolas Nagot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.